Federal Barriers to Addressing the Opioid Epidemic.
作者信息
Kleinman Robert A, Morris Nathaniel P
机构信息
Stanford University School of Medicine, Palo Alto, CA, USA.
出版信息
J Gen Intern Med. 2020 Apr;35(4):1304-1306. doi: 10.1007/s11606-020-05721-5. Epub 2020 Feb 19.
Abstract
摘要
相似文献
1
Federal Barriers to Addressing the Opioid Epidemic.解决阿片类药物流行问题的联邦障碍。
J Gen Intern Med. 2020 Apr;35(4):1304-1306. doi: 10.1007/s11606-020-05721-5. Epub 2020 Feb 19.
2
Finding Hope in Combating the American Opioid Epidemic.在美国抗击阿片类药物流行中寻找希望。
Issues Ment Health Nurs. 2022 Oct;43(10):893-894. doi: 10.1080/01612840.2022.2127573.
3
A rural perspective on the opioid crisis.对阿片类药物危机的乡村视角
Nurs Manage. 2019 Aug;50(8):6. doi: 10.1097/01.NUMA.0000575336.16325.45.
4
Addressing long overdue social and structural determinants of the opioid epidemic.解决阿片类药物流行长期被忽视的社会和结构决定因素。
Drug Alcohol Depend. 2021 May 1;222:108679. doi: 10.1016/j.drugalcdep.2021.108679. Epub 2021 Mar 18.
5
The American Opioid Epidemic: Population Health Implications and Potential Solutions. Report from the National Stakeholder Panel.美国阿片类药物流行：对人群健康的影响及潜在解决方案。国家利益相关者小组报告。
Popul Health Manag. 2016 Mar;19 Suppl 1:S1-10. doi: 10.1089/pop.2015.0144.
6
Addressing the Intersection of Infectious Disease Epidemics and Opioid and Substance Use Epidemics.应对传染病流行与阿片类药物及物质使用流行的交叉问题。
Infect Dis Clin North Am. 2020 Sep;34(3):xiii-xiv. doi: 10.1016/j.idc.2020.06.016.
7
Reexamining Medicaid Patient Review and Restriction Programs Amid the Evolving Opioid Epidemic.在不断演变的阿片类药物流行背景下重新审视医疗补助患者审查与限制计划
JAMA Intern Med. 2022 Aug 1;182(8):789-790. doi: 10.1001/jamainternmed.2022.1952.
8
Confronting a crisis: An open letter to America's physicians on the opioid epidemic.直面危机：致美国医生的一封关于阿片类药物流行问题的公开信。
W V Med J. 2016 Jul-Aug;112(4):9.
9
Upsurges in the joblessness and opioid epidemics in the United States after the COVID-19 epidemic: the plight of the jobless patient in the clinic.新冠疫情后美国失业率和阿片类药物流行率的激增：诊所中失业患者的困境。
Pain. 2021 Jun 1;162(6):1608-1611. doi: 10.1097/j.pain.0000000000002253.
10
Why Marijuana Will Not Fix the Opioid Epidemic.为何大麻无法解决阿片类药物成瘾危机。
Mo Med. 2018 May-Jun;115(3):191-193.
引用本文的文献
1
How competing needs after incarceration lead to adverse health outcomes among people who use criminalized drugs.监禁后的各种相互竞争的需求如何导致使用被定罪药物者出现不良健康结果。
BMC Glob Public Health. 2025 May 1;3(1):36. doi: 10.1186/s44263-025-00152-y.
2
Evaluation of a Program Designed to Support Implementation of Prescribing Medication for Treatment of Opioid Use Disorder in Primary Care Practices.一项旨在支持在初级保健机构实施开具药物治疗阿片类物质使用障碍方案的评估。
Ann Fam Med. 2025 Jan 27;23(1):44-51. doi: 10.1370/afm.3190.
3
Acceptability and anticipated effectiveness of a safe supply of opioids, among people who inject opioids in King County, WA.在华盛顿州金县注射阿片类药物的人群中，安全供应阿片类药物的可接受性和预期效果。
Int J Drug Policy. 2024 May;127:104389. doi: 10.1016/j.drugpo.2024.104389. Epub 2024 Mar 24.
4
Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.根据保留定义衡量 HIV 合并阿片类物质使用障碍人群在丁丙诺啡治疗各阶段的时间及其与可卡因和危险饮酒的关系。
Addict Sci Clin Pract. 2023 Sep 2;18(1):51. doi: 10.1186/s13722-023-00408-8.
5
Prevalence of Substance Abuse Among Trauma Patients in Rural West Virginia.西弗吉尼亚州农村地区创伤患者药物滥用的患病率
Cureus. 2023 Mar 21;15(3):e36468. doi: 10.7759/cureus.36468. eCollection 2023 Mar.
6
COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.美沙酮口服药物维持治疗点与 COVID-19 相关的政策变化：一项针对阿片类药物治疗项目领导层的多州调查。
Subst Abus. 2022;43(1):633-639. doi: 10.1080/08897077.2021.1986768. Epub 2021 Oct 19.
7
Opioid Use Disorder: Treatments and Barriers.阿片类物质使用障碍：治疗方法与障碍
Cureus. 2021 Feb 6;13(2):e13173. doi: 10.7759/cureus.13173.
本文引用的文献
1
Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction.美沙酮至关重要：美国可从全球治疗阿片类药物成瘾工作中学到什么。
J Gen Intern Med. 2019 Jun;34(6):1039-1042. doi: 10.1007/s11606-018-4801-3. Epub 2019 Feb 6.
2
Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver.丁丙诺啡管制放松与阿片类物质使用障碍的主流治疗：X豁免权。
JAMA Psychiatry. 2019 Mar 1;76(3):229-230. doi: 10.1001/jamapsychiatry.2018.3685.
3
Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.持 DEA 豁免权开具丁丙诺啡用于治疗阿片类药物使用障碍的提供者的地理分布：5 年更新。
J Rural Health. 2019 Jan;35(1):108-112. doi: 10.1111/jrh.12307. Epub 2018 Jun 20.
4
Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction†.海洛因试验：对丁丙诺啡处方治疗难治性海洛因成瘾的随机试验的系统评价和荟萃分析。
Br J Psychiatry. 2015 Jul;207(1):5-14. doi: 10.1192/bjp.bp.114.149195.
5
Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.2002年至2011年期间，医生丁丙诺啡豁免权的增长增加了获得阿片类激动剂治疗的可能性。
Health Aff (Millwood). 2015 Jun;34(6):1028-34. doi: 10.1377/hlthaff.2014.1205.
6
Supervised injection services: what has been demonstrated? A systematic literature review.监督下的注射服务：已证实了什么？一项系统的文献综述。
Drug Alcohol Depend. 2014 Dec 1;145:48-68. doi: 10.1016/j.drugalcdep.2014.10.012. Epub 2014 Oct 23.
Zotero 插件